Gilead Sciences, Inc. (GILD) Financial Ratios
30 years of historical data (1995–2024) · Healthcare · Drug Manufacturers - General
EV/EBITDA
↑
42.12
↑+155% vs avg
5yr avg: 16.51
30Y Low6.1·High73.3
P/FCF
↑
16.48
↑+47% vs avg
5yr avg: 11.25
30Y Low6.0·High123.6
P/B Ratio
↑
8.89
↑+85% vs avg
5yr avg: 4.80
30Y Low2.4·High15.9
ROE
↑
2.3%
↑-86% vs avg
5yr avg: 16.4%
30Y Low-49%·High104%
Debt/EBITDA
↑
6.03
↑+59% vs avg
5yr avg: 3.80
30Y Low0.0·High6.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GILD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Gilead Sciences, Inc. trades at 358.7x earnings, 100% above its 5-year average of 179.5x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 1519%. On a free-cash-flow basis, the stock trades at 16.5x P/FCF, 47% above the 5-year average of 11.2x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $169.8B | $115.9B | $101.9B | $108.3B | $91.6B | $73.6B | $83.0B | $81.8B | $94.5B | $97.2B | $153.9B |
| Enterprise Value | $186.5B | $132.6B | $120.8B | $128.2B | $113.0B | $99.0B | $95.9B | $91.2B | $120.4B | $115.4B | $163.1B |
| P/E Ratio → | 358.68 | 243.08 | 18.00 | 23.59 | 14.73 | 598.15 | 15.40 | 15.00 | 20.41 | 7.20 | 8.50 |
| P/S Ratio | 5.91 | 4.03 | 3.76 | 3.97 | 3.36 | 2.98 | 3.70 | 3.70 | 3.62 | 3.20 | 4.72 |
| P/B Ratio | 8.89 | 6.02 | 4.48 | 5.11 | 4.35 | 4.04 | 3.66 | 3.80 | 4.61 | 5.02 | 8.05 |
| P/FCF | 16.48 | 11.25 | 13.73 | 12.98 | 8.48 | 9.79 | 9.97 | 10.94 | 8.36 | 5.97 | 7.51 |
| P/OCF | 15.68 | 10.71 | 12.73 | 11.94 | 8.05 | 9.01 | 9.07 | 9.74 | 7.94 | 5.70 | 7.24 |
P/E links to full P/E history page with 30-year chart
GILD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Gilead Sciences, Inc.'s enterprise value stands at 42.1x EBITDA, 155% above its 5-year average of 16.5x. The Healthcare sector median is 14.1x, placing the stock at a 199% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.61 | 4.46 | 4.70 | 4.14 | 4.01 | 4.27 | 4.12 | 4.61 | 3.80 | 5.00 |
| EV / EBITDA | 42.12 | 29.95 | 11.73 | 13.59 | 9.44 | 17.83 | 16.86 | 9.47 | 7.82 | 6.14 | 7.00 |
| EV / EBIT | 112.24 | 79.57 | 15.48 | 18.99 | 12.18 | 37.31 | 15.59 | 10.27 | 8.22 | 6.39 | 7.30 |
| EV / FCF | — | 12.87 | 16.28 | 15.36 | 10.46 | 13.17 | 11.53 | 12.20 | 10.65 | 7.08 | 7.96 |
GILD Profitability
Margins and return-on-capital ratios measuring operating efficiency
Gilead Sciences, Inc. earns an operating margin of 5.8%. Operating margins have compressed from 26.9% to 5.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 2.3% is modest. ROIC of 3.2% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3% | 78.3% | 76.0% | 79.3% | 75.8% | 81.5% | 79.2% | 78.1% | 83.3% | 86.0% | 87.7% |
| Operating Margin | 5.8% | 5.8% | 28.0% | 26.9% | 36.3% | 16.5% | 19.1% | 37.1% | 54.1% | 58.0% | 68.0% |
| Net Profit Margin | 1.7% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% | 24.0% | 24.7% | 17.7% | 44.4% | 55.5% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.3% | 2.3% | 25.8% | 21.7% | 31.7% | 0.6% | 24.4% | 26.0% | 23.2% | 70.2% | 103.7% |
| ROA | 0.8% | 0.8% | 9.0% | 7.0% | 9.1% | 0.2% | 8.6% | 8.1% | 7.3% | 24.8% | 41.9% |
| ROIC | 3.2% | 3.2% | 13.8% | 13.2% | 17.3% | 7.7% | 9.7% | 15.9% | 25.2% | 40.2% | 71.6% |
| ROCE | 3.4% | 3.4% | 14.8% | 13.5% | 17.5% | 7.5% | 8.2% | 14.7% | 26.5% | 39.4% | 62.8% |
GILD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Gilead Sciences, Inc. carries a Debt/EBITDA ratio of 6.0x, which is highly leveraged (93% above the sector average of 3.1x). Net debt stands at $16.7B ($26.7B total debt minus $10.0B cash). Interest coverage of just 1.7x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.39 | 1.39 | 1.10 | 1.19 | 1.27 | 1.72 | 1.09 | 1.27 | 1.64 | 1.36 | 1.15 |
| Debt / EBITDA | 6.03 | 6.03 | 2.43 | 2.67 | 2.23 | 5.66 | 4.32 | 2.84 | 2.18 | 1.40 | 0.95 |
| Net Debt / Equity | — | 0.87 | 0.83 | 0.93 | 1.01 | 1.39 | 0.57 | 0.44 | 1.27 | 0.94 | 0.48 |
| Net Debt / EBITDA | 3.78 | 3.78 | 1.84 | 2.10 | 1.78 | 4.58 | 2.28 | 0.97 | 1.68 | 0.96 | 0.40 |
| Debt / FCF | — | 1.62 | 2.55 | 2.38 | 1.98 | 3.38 | 1.56 | 1.25 | 2.30 | 1.11 | 0.45 |
| Interest Coverage | 1.70 | 1.70 | 8.06 | 7.84 | 9.91 | 4.14 | 4.31 | 7.61 | 12.63 | 18.29 | 32.26 |
GILD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.60x means Gilead Sciences, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.29x to 1.60x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.60 | 1.60 | 1.43 | 1.29 | 1.27 | 1.40 | 3.10 | 3.38 | 2.74 | 2.12 | 2.50 |
| Quick Ratio | 1.45 | 1.45 | 1.27 | 1.15 | 1.13 | 1.26 | 3.01 | 3.30 | 2.67 | 1.95 | 2.31 |
| Cash Ratio | 0.96 | 0.96 | 0.64 | 0.57 | 0.56 | 0.65 | 2.50 | 2.84 | 2.19 | 1.29 | 1.48 |
| Asset Turnover | — | 0.49 | 0.44 | 0.43 | 0.40 | 0.36 | 0.36 | 0.35 | 0.37 | 0.53 | 0.63 |
| Inventory Turnover | 3.66 | 3.66 | 3.64 | 3.75 | 4.08 | 2.72 | 5.07 | 5.96 | 5.46 | 2.68 | 2.05 |
| Days Sales Outstanding | — | 56.11 | 62.73 | 63.91 | 60.06 | 72.32 | 58.24 | 54.88 | 53.84 | 54.22 | 65.46 |
GILD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Gilead Sciences, Inc. returns 3.0% to shareholders annually — split between a 2.3% dividend yield and 0.7% buyback yield. The payout ratio exceeds 100% at 816.3%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery. The earnings yield of 0.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.3% | 3.4% | 3.7% | 3.4% | 3.9% | 4.7% | 3.9% | 3.6% | 2.9% | 2.5% | 1.2% |
| Payout Ratio | 816.3% | 816.3% | 67.2% | 80.8% | 57.9% | 2804.1% | 59.8% | 54.5% | 59.0% | 18.2% | 10.3% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.3% | 0.4% | 5.6% | 4.2% | 6.8% | 0.2% | 6.5% | 6.7% | 4.9% | 13.9% | 11.8% |
| FCF Yield | 6.1% | 8.9% | 7.3% | 7.7% | 11.8% | 10.2% | 10.0% | 9.1% | 12.0% | 16.8% | 13.3% |
| Buyback Yield | 0.7% | 1.0% | 1.0% | 1.3% | 0.6% | 2.2% | 2.1% | 3.5% | 1.0% | 11.3% | 6.5% |
| Total Shareholder Yield | 3.0% | 4.4% | 4.7% | 4.7% | 4.5% | 6.8% | 6.0% | 7.2% | 3.9% | 13.8% | 7.7% |
| Shares Outstanding | — | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.4B | $1.5B |
Peer Comparison
Compare GILD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GILDYou | $170B | 358.7 | 42.1 | 16.5 | 78.3% | 5.8% | 2.3% | 3.2% | 6.0 |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 BMY | $115B | 16.4 | 9.2 | 9.0 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 AMGN | $179B | 23.3 | 14.1 | 22.1 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 BIIB | $28B | 21.6 | 11.4 | 13.7 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 REGN | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 VRTX | $109B | 27.9 | 21.7 | 34.1 | 85.0% | 39.4% | 22.5% | 23.0% | 0.8 |
 MRK | $280B | 15.6 | 10.8 | 22.7 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 JNJ | $541B | 38.8 | 18.8 | 27.3 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 INCY | $20B | 15.6 | 11.8 | 14.7 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full GILD Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy GILD Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See GILD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GILD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GILD vs ABBV
Side-by-side business, growth, and profitability comparison vs AbbVie Inc..
Start ComparisonGILD — Frequently Asked Questions
Quick answers to the most common questions about buying GILD stock.
What is Gilead Sciences, Inc.'s P/E ratio?
Gilead Sciences, Inc.'s current P/E ratio is 358.7x. The historical average is 28.9x. This places it at the 100th percentile of its historical range.
What is Gilead Sciences, Inc.'s EV/EBITDA?
Gilead Sciences, Inc.'s current EV/EBITDA is 42.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.4x.
What is Gilead Sciences, Inc.'s ROE?
Gilead Sciences, Inc.'s return on equity (ROE) is 2.3%. The historical average is 21.6%.
Is GILD stock overvalued?
Based on historical data, Gilead Sciences, Inc. is trading at a P/E of 358.7x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Gilead Sciences, Inc.'s dividend yield?
Gilead Sciences, Inc.'s current dividend yield is 2.29% with a payout ratio of 816.3%.
What are Gilead Sciences, Inc.'s profit margins?
Gilead Sciences, Inc. has 78.3% gross margin and 5.8% operating margin.
How much debt does Gilead Sciences, Inc. have?
Gilead Sciences, Inc.'s Debt/EBITDA ratio is 6.0x, indicating high leverage. A ratio above 4x may signal elevated financial risk.